anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Compared with stem cells, exosomes as a kind of nanoscale carriers intrinsically loaded with diverse bioactive molecules, which had the advantages of high safety, small size, and ethical considerations in the treatment of myocardial infarction, but there are still problems such as impaired stability and rapid dissipation. Here, we introduce a bioengineered injectable hyaluronic acid hydrogel designed to optimize local delivery efficiency of trophoblast stem cells derived-exosomes. Its hyaluronan components adeptly emulates the composition and modulus of pericardial fluid, meanwhile preserving the bioactivity of nanoscale exosomes. Additionally, a meticulously designed hyperbranched polymeric cross-linker facilitates a gentle cross-linking process among hyaluronic acid molecules, with disulfide bonds in its molecular framework enhancing biodegradability and conferring a unique controlled release capability. This innovative hydrogel offers the added advantage of minimal invasiveness during administration into the pericardial space, greatly extending the retention of exosomes within the myocardial region. In vivo, this hydrogel has consistently demonstrated its efficacy in promoting cardiac recovery, inducing anti-fibrotic, anti-inflammatory, angiogenic, and anti-remodeling effects, ultimately leading to a substantial improvement in cardiac function. Furthermore, the implementation of single-cell RNA sequencing has elucidated that the pivotal mechanism underlying enhanced cardiac function primarily results from the promoted clearance of apoptotic cells by myocardial fibroblasts.
The invention relates to a process for preparing a wet granulate suitable for use in manufacturing tablets by compression and compaction thereof. The process comprises first forming an intimate mixture of particulate-solid materials including pharmacologically or like active matter and tabletting aids. Then one predetermines a quantity of granulating fluid needed to convert the entire particulate-solid mixture into a desired moist, coherent, non-pasty mass as known per se but homogenizes part only of the particulate-solid materials, separately from the remainder thereof, with a chosen amount of granulating fluid, that chosen amount being at least 90% by weight of the aforesaid predetermined quantity of granulating fluid, so as to form a substantially-homogeneous slurry wherein the percentage by weight of solids in the slurry, namely: Total Solids, i.e. both dissolved and undissolved x 100 Total Slurry, i.e. fluids plus total solids is at least about 25% w/w. Thereafter, the remaining part of the particulate-solid material is moistened in the manner of <<wet-granulation>> as known per se but with the thus-prepared slurry (and then as necessary with the balance of the granulating fluid, if any) so as thus to form the desired substantially-uniform, moist, coherent, non-pasty mass ready for granulation.
Topiramate is a sulfamate-substituted monosaccharide.

Topiramate capsules, USP are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food.

Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C12H21NO8S and a molecular weight of 339.36. Topiramate is designated chemically as 2,3:4,5­-Di-O-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula:

Topiramate capsules, USP contain topiramate-coated beads in a hard gelatin capsule. The inactive ingredients are black ink, cellulose acetate, gelatin, mannitol, povidone, sodium lauryl sulfate, sugar spheres (sucrose and starch) and titanium dioxide.

FDA approved dissolution test specifications differ from USP.
This is a prospective study of epilepsy biomarkers in a total of 100 subjects of ages 4-18. Participants will spend about 5 hours at the Massachusetts General Hospital (MGH) Athinoula A. Martinos Center for Biomedical Imaging. They will undergo training on a memory task concurrent with EEG/MEG recordings. During the EEG, subjects will wear headphones that will deliver a quiet pink noise stimulus intermittently during a nap. The auditory stimulus will be calibrated in volume to not cause arousals. After napping, subjects will undergo cognitive testing and memory task testing.
Patients receive STEMVAC ID and sargramostim ID on day 14 (+3 days) of the 21-day maintenance therapy cycle for a series of 3 vaccine doses and a booster vaccine 9 weeks after the third vaccine dose. Patients also undergo CT and biopsy during screening and on the trial, as well as blood sample collection on trial and during follow-up.
A computer system includes a data storage module. The data storage module receives, stores, and provides access to data related to payment requests submitted to an insurance company by service providers. The data storage module is coupled to a computer processor. Also coupled to the computer processor are a program memory, an input device and an output device. The input device is used to input information to identify a first service provider. The display device is used to display data about other service providers who are associated with the same insurance claims as the first service provider. The data displayed about the other service providers includes taxpayer identification numbers (TINs).
The data collected by the 2011 Bangladesh Demographic Health Survey (BDHS), conducted by the National Institute for Population Research and Training (Ministry of Health and Family Welfare, Bangladesh), will be used for the purpose of this study. in the BDHS 2011, A nationally representative household-based sample was created through a stratified, multistage cluster sampling strategy in which 600 primary sampling units were constructed (207 in urban areas and 393 in rural areas). The primary sampling units were derived from a sampling frame created for the 2001 Bangladeshi census from seven divisions of Bangladesh. Households were selected randomly from each primary sampling unit. The data pertaining to the socioeconomic and sociodemographic factors were collected using a structured open-ended interview. The questionnaire used for this purpose was modeled on the MEASURE DHS questionnaires. Prior to the use, these questionnaires were adapted for the use in Bangladesh through a series of meetings with a Technical Working Group (TWG) that comprised of representatives from the National Institute of Population Research and Training (NIPORT,) Mitra and Associates, the International Centre for Diarrheal Diseases and Control in Bangladesh (ICDDR, B), USAID/Bangladesh, and MEASURE DH. The questionnaires were drafted in English and then translated into Bangla which is the national language of Bangladesh. The translations were reviewed by the experts as well as by the volunteers and a pilot study was conducted to validate the same. Of the total of 17,964 selected households, face-to-face interviews were successfully completed for 17,141 corresponding to a household response rate of 98%. The subjects for the examination of anemia were 2320 children aged 6-59 months, were raised from every third household of the BDHS sample. After excluding subjects with missing data, a total of 2068 individuals were selected for this analysis.
NEW MATERIAL:The antibiotic substance YS-02931K-beta of formula. USE:It has strong antimicrobial activity against Gram-positive bacteria, yeasts and fungi, exhibits the activity especially against cutaneous fungi and Gram-positive bacteria and is useful as a medicinal drug. PREPARATION:A microbial strain belonging to Nocardia genus and capable of producing YS-02931K-beta substance, e.g. Nocardia sp YS-02931K strain (FERM P-7962) is cultured, and the titled compound is separated from the culture liquid. The cultivation is carried out by the method for the cultivation of conventional microorganisms and preferably by the submerged cultivation in liquid medium. Any medium containing nutrient source assimilable by Nocardia sp YS-02931K strain may be used as the medium for the present cultivation.
OBJECTIVES: Variants in NEXMIF had been reported associated with intellectual disability (ID) without epilepsy or developmental epileptic encephalopathy (DEE). It is unkown whether NEXMIF variants are associated with epilepsy without ID. This study aims to explore the phenotypic spectrum of NEXMIF and the genotype-phenotype correlations.
MATERIALS AND METHODS: Trio-based whole-exome sequencing was performed in patients with epilepsy. Previously reported NEXMIF variants were systematically reviewed to analyze the genotype-phenotype correlations.
RESULTS: Six variants were identified in seven unrelated cases with epilepsy, including two de novo null variants and four hemizygous missense variants. The two de novo variants were absent in all populations of gnomAD and four hemizygous missense variants were absent in male controls of gnomAD. The two patients with de novo null variants exhibited severe developmental epileptic encephalopathy. While, the patients with hemizygous missense variants had mild focal epilepsy with favorable outcome. Analysis of previously reported cases revealed that males with missense variants presented significantly higher percentage of normal intellectual development and later onset age of seizure than those with null variants, indicating a genotype-phenotype correlation.
CONCLUSION: This study suggested that NEXMIF variants were potentially associated with pure epilepsy with or without intellectual disability. The spectrum of epileptic phenotypes ranged from the mild epilepsy to severe developmental epileptic encephalopathy, where the epileptic phenotypes variability are potentially associated with patients' gender and variant type.
TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.
PURPOSE: A pharmaceutical composition containing Scutellaria baicalensis is provided to effectively suppress increase of auditory threshold and improve drug compliance. CONSTITUTION: A pharmaceutical composition for preventing or treating auditory disorder contains Scutellaria baicalensis extract as an active ingredient. The auditory disorder is noise-induced hearing loss. The Scutellaria baicalensis extract is isolated from Scutellaria baicalensis using water, alcohol of C1-C4 or their mixture. The Scutellaria baicalensis is Scutellaria viscidula Beg, Scutellaria amoena C.H. Wright, Scutellaria rehderiana Diels, Scutellaria Likiangensis Diels, Scutellaria Likiangensis Diels or Scutellaria Hypericifolia Levl.
PURPOSE:To allow the execution of a remote control by connecting a host computer and a subordinate computer by a communicating line for signal transmission and reception. CONSTITUTION:The push of a preferential switch 14 of a remote control panel 3 is ineffectual even if this switch is pushed by the host computer 4 when a preferential switch 10 is pushed. A motor 9 is run when a run switch 11 is pushed. The motor 9 stops when a stop switch 12 is pushed. The state of the motor 9 is displayed as the run switch 11 is lighted or put out by the host computer 4 on a machine side control panel 2 side and the run switch 15 is lighted or put out by the subordinate computer 5 on a remote control panel 3 side as well. The motor 9 is run by pushing the run switch 15 after the preferential switch 14 is pushed. The motor 9 is stopped by pushing the stop switch 16. This state is displayed as the run switches 11, 15 of the two control panels 2, 3 are lighted or put out by the host computer 4 and the subordinate computer 5. The need for the remedy to noise is eliminated in this way and the remote control is possible.
The disclosure herein relates to embodiments of compositions and methods in connection with polymeric micelles including PEG-phospholipids. Embodiments also relate to the controlled release of pharmaceutical agents in the context of drug delivery. Further disclosed are embodiments of PEG-DSPE/Cholesterol micelle formulations prepared with an antifungal agent, Amphotericin B, with capabilities including slow release of the agent in a deaggregated state. In embodiments, micellar preparations with Amphotericin B are compatible with solubility in aqueous salt solutions, thus allowing for concurrent co-administration of other pharmaceutical agents and/or sodium supplementation. In embodiments, polymeric micelle compositions are employed in combination antifungal therapeutic approaches such as Amphotericin B and other antifungal agents. Also disclosed herein are compositions and methods relating to combinations including AmB:PEG-DSPE, rapamycin:PEG-DSPE, and/or 5-fluorocytosine.
Participants will be randomized into 7 cohorts to receive single oral dose of JMKX003142 on Day 1. The doses in each cohort will be escalated based on the safety and pharmacokinetics (PK) / Pharmacodynamics (PD) data of the previous cohort.
BACKGROUND: Patients with irritable bowel syndrome (IBS) often have chronic low-grade inflammation in the intestinal mucosa. Some dietary components are known to be associated with inflammation. However, there is currently limited research on the relationship between dietary inflammatory potential and the risk of IBS.
METHODS: A total of 129,408 participants in the UK Biobank were included in this study. Energy-Adjusted Dietary Inflammatory Index (E-DII) based on 26 nutrients and the Empirical Dietary Inflammatory Pattern (EDIP) based on 17 food groups were constructed, and on the basis of the tertiles, the continuous score was categorized into proinflammatory, neutral, and antiinflammatory categories. Associations between IBS and E-DII and EDIP were investigated by multivariable Cox proportional hazard models. Potential confounders including sociodemographic, lifestyle, body mass index (BMI), psychological state, type 2 diabetes, and thyroiditis were adjusted. In addition, subgroup analysis and sensitivity analysis were also performed. Finally, a two-sample Mendelian randomization (MR) analysis was employed to explore the independent causality of nutrients and dietary-derived serum antioxidants with IBS.
RESULTS: In the cohort study, over a median follow-up period of 13.26 years, 2421(1.87%) participants developed IBS. In the E-DII categories, after adjusting for the confounders, individuals in the proinflammatory diet category had a higher risk of IBS compared with the antiinflammatory category (HR 1.15, 95% CI 1.03-1.28, p = 0.015, p trend = 0.017) and neutral category (HR 1.13, 95% CI 1.01-1.26, p = 0.030, p trend = 0.017). In the EDIP categories, after adjusting for the confounders, individuals in the proinflammatory diet category had a higher risk of IBS compared with antiinflammatory category (HR 1.19, 95% CI 1.06-1.33, p = 0.002, p trend = 0.002) but no significant association compared with neutral category (HR 1.10, 95% CI 0.99-1.23, p = 0.067, p trend = 0.002). In the MR analysis, genetically determined intake levels of 16 nutrients and 6 dietary sources of circulating antioxidants did not have a causal effect on IBS.
CONCLUSIONS: Our findings indicate that proinflammatory dietary components are independent risk factors for IBS. However, there is no causal relationship between individual nutrient intake or serum antioxidants from dietary sources and IBS.
The invention discloses a drug for fumigating cold arthralgia. A formula of the drug consists of the following Chinese herbal medicine materials in weight portion: ephedra, prepared aconite, radix aconiti, radix aconiti feri, cinnamon, pepper, rhizoma ligustici wallichii, umbellate pore fungus, parsnip, brassica alba boiss, clematis chinensis, trberculate speranskia herb, dandelion and fructus liquidambaris. The drug is characterized in that oarweed, allium victorialis and vinegar are used as primers. The drug has the advantages of uneasy recrudescence, no toxic side effect after healing. A slight patient can be healed after one treatment period; and a serious patient can be healed after two to three treatment periods. The effective rate is 98 percent; and the cure rate is over 89 percent.
Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
Patients receive oral sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
R115777 (Tipifarnib) is a farnesyltransferase inhibitor that blocks the post-translational isoprenylation of ras and other farnesylated proteins. The ras proteins are integral in cell signaling pathways, and farnesylation is essential for the function of both mutant and non-mutant ras proteins. Patients with neurofibromatosis type 1 (NF1) have an increased risk of developing tumors of the central and peripheral nervous system, and there are no standard treatment options, other than surgery, available for these tumors. Neurofibromin, which is the product of the NF1 gene, contains a domain with significant homology to ras GTPase-activating proteins (GAP). Although NF1 patients lack germline ras mutations, the decreased levels of neurofibromin have been shown to be associated with a constitutively activated ras-GTP status. Thus, upstream inhibition of ras farnesylation may inhibit growth of tumors in NF1 patients. A randomized, cross-over, double-blinded, placebo-controlled pediatric phase II trial of oral R115777 will be performed in children and young adults with NF1, who have progressive, plexiform neurofibroma(s) to determine the effect of this novel anticancer drug on the rate of growth of neurofibromas. The endpoint of the trial is time to progression. R115777 will be administered orally at a dose of 200 mg/m(2) twice daily for cycles of 21 days followed by a 7 day rest period based on the results of our prior pediatric phase I trial.
The present invention relates to a bioconversion product of a nostoc commune extract or an anti-microbial composition comprising the extract thereof and, more specifically, to a bioconversion product of a nostoc commune extract, obtained by biologically converting the nostoc commune extract into Bacillus sp. JD3-7, or an anti-microbial composition comprising the extract of the bioconversion product. In addition, the present invention relates to a bioconversion method of a nostoc commune extract and Bacillus sp. JD3-7 strain, or a fermenting strain used therein. The anti-microbial composition of the present invention utilizes nostoc commune, or a bio resource that has hardly been utilized conventionally to have excellent anti-microbial activity against Propionibacterium acnes, E-coli and Salmonella enterica. In particular, the anti-microbial composition of the present invention has high anti-microbial activity against Propionibacterium acnes, or a cause of acne and can be safely used to the skin, thereby being useful as a natural anti-microbial material for cosmetics for preventing, treating, or alleviating acne.
BACKGROUND: Gallbladder cancer (GBC) is the most common biliary tract malignancy and has a poor prognosis. The clinical significance of focal vs diffuse GBC remains unclear.
METHODS: A retrospective review was conducted on all patients with non-metastatic GBC at a quaternary care center. Pathology was reviewed, and gallbladder cancer pattern was defined based on the extent of mucosal involvement; "diffuse" if the tumor was multicentric or "focal" if the tumor was only in a single location. Patients undergoing liver resection and portal lymphadenectomy were considered to have definitive surgery. The primary outcome was overall survival and assessed by Kaplan-Meier curves.
RESULTS: 63 patients met study criteria with 32 (50.7%) having diffuse cancer. No difference was observed in utilization of definitive surgery between the groups (14 [43.8%] with focal and 12 [38.7%] with diffuse, P = .88). Lymphovascular invasion (P = .04) and higher nodal stage (P = .04) were more common with diffuse GBC. Median overall survival was significantly improved in those with focal cancer (5.1 vs 1.2 years, P = .02). Although not statistically significant, this difference in overall survival persisted in patients who underwent definitive surgery (4.3 vs 2.4 years, P = .70).
DISCUSSION: Patients with diffuse involvement of the gallbladder mucosa likely represent a subset with aggressive biology and worse overall survival compared to focal disease. These findings may aid surgeons in subsequent surgical and medical decision-making for patients with GBC.
BACKGROUND: N6-methyladenosine (m6A) modification controls the stability, splicing, and translation of mRNA, which is important in the development of illnesses. Wilson's disease (WD) is an autosomal recessive liver copper metabolic disorder that causes liver fibrosis. The role of m6A methylation in WD-induced liver fibrosis development is still unclear. Thus, the goal of this study was to examine the scope of m6A methylation and further explore the potential targets related to WD-induced liver fibrosis.
RESULTS: A total of 1930 significantly different m6A peaks were found on 1737 mRNAs, of which 993 were hypermethylated and 744 were hypomethylated when comparing normal and WD-induced liver fibrosis mice (n = 3). In parallel, 1261 differentially expressed mRNAs, comprising 557 upregulated and 704 downregulated mRNAs, were found. Overall, 114 mRNAs with significant changes in m6A levels and RNA expression were identified via joint analysis. Then, through PPI network construction and functional enrichment analysis, 12 hub genes were identified, these genes were mainly enriched in the inflammatory response and immunomodulation, and they are associated with immune cell infiltration.
CONCLUSIONS: The significant difference in the amount of mRNA m6A modifications indicates that m6A modification is involved in the progression of WD-induced liver fibrosis, and theidentified hub genes are involved in inflammation and immune infiltration. These results may provide insights for subsequent studies on potential regulatory mechanisms.